Licensing-based Revenue ModelAn asset-light licensing model links Iconovo’s revenue to partner-led drug programs via upfront fees, milestones and royalties. Structurally this can scale without proportional capex, diversify revenue sources across partners, and produce long-term recurring royalties if partnered drugs reach commercial stages.

Low Leverage And Sizable Equity BaseA low debt load and meaningful equity provide financial flexibility and resilience. This balance-sheet strength reduces near-term refinancing risk, supports continued R&D and partner development work, and gives the company runway to pursue licensing deals or absorb development cycles without immediate capital stress.

Focused Inhalation Platform ExpertiseConcentration on dry powder inhaler platforms builds specialized IP and technical know-how that are attractive to respiratory drug developers. This domain focus can create competitive differentiation, shorten partner time-to-device fit, and increase the likelihood of long-term partnerships and royalty streams in inhalation therapies.

Bears Say

Sharp And Multi-year Revenue DeclineSustained revenue contraction undermines the company’s ability to absorb fixed R&D and operating costs and weakens bargaining power with partners. Persistently falling sales limit internal reinvestment capacity, increase dependence on new licensing wins, and raise the risk that operating losses persist absent a durable reversal in partner activity.

Persistent Operating Cash BurnConsistent negative operating cash flow forces reliance on existing equity or fresh financing to fund operations and development. Over the medium term this constrains strategic optionality, increases dilution or debt risk if raised, and can delay or limit investment in product development and commercialization necessary to generate future licensing income.

Sizable Operating And Net LossesLarge recurring losses indicate the business is not near break-even and may erode equity if sustained. Ongoing negative margins weaken returns on invested capital, reduce internal funding for growth initiatives, and make the company more sensitive to partner setbacks or longer development timelines required to convert licensing agreements into royalties.

ICO FAQ

What was Iconovo AB’s price range in the past 12 months?

Iconovo AB lowest stock price was kr0.91 and its highest was kr3.60 in the past 12 months.

What is Iconovo AB’s market cap?

Iconovo AB’s market cap is kr84.52M.

When is Iconovo AB’s upcoming earnings report date?

Iconovo AB’s upcoming earnings report date is Apr 24, 2026 which is in 50 days.

How were Iconovo AB’s earnings last quarter?

Iconovo AB released its earnings results on Feb 12, 2026. The company reported -kr0.24 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.24.

Is Iconovo AB overvalued?

According to Wall Street analysts Iconovo AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Iconovo AB pay dividends?

Iconovo AB does not currently pay dividends.

What is Iconovo AB’s EPS estimate?

Iconovo AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Iconovo AB have?

Iconovo AB has 74,800,380 shares outstanding.

What happened to Iconovo AB’s price movement after its last earnings report?

Iconovo AB reported an EPS of -kr0.24 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.143%.

Which hedge fund is a major shareholder of Iconovo AB?

Currently, no hedge funds are holding shares in SE:ICO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Iconovo AB

Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler, as well as provides customized inhalation solutions. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius AB (publ) to develop inhalation product to treat COPD. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.